Key Points
- Director Gregg Williams purchased 1,587,301 shares on April 15 at an average price of $1.26 (~$1.999M), bringing his direct holding to 32,944,484 shares (~$41.51M) — a 5.06% increase and part of multiple large insider buys this year.
- Vivani Medical (NASDAQ:VANI) has a market cap of about $110.9M and a 52‑week range of $0.92–$1.92; the company slightly beat its last quarterly EPS estimate (‑$0.09 vs. ‑$0.10) while analysts hold an average "Hold" rating with a $3.50 target after HC Wainwright cut its target from $4.00 to $3.50.
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams bought 1,587,301 shares of the business's stock in a transaction on Wednesday, April 15th. The stock was purchased at an average price of $1.26 per share, for a total transaction of $1,999,999.26. Following the purchase, the director directly owned 32,944,484 shares in the company, valued at approximately $41,510,049.84. This represents a 5.06% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Gregg Williams also recently made the following trade(s):
- On Sunday, March 15th, Gregg Williams bought 1,575,231 shares of Vivani Medical stock. The stock was purchased at an average price of $1.07 per share, for a total transaction of $1,685,497.17.
- On Tuesday, January 27th, Gregg Williams bought 1,351,351 shares of Vivani Medical stock. The stock was purchased at an average price of $1.48 per share, for a total transaction of $1,999,999.48.
Vivani Medical Stock Performance
NASDAQ VANI opened at $1.31 on Friday. The stock has a market capitalization of $110.89 million, a price-to-earnings ratio of -3.05 and a beta of 2.16. The stock's 50 day moving average price is $1.16 and its two-hundred day moving average price is $1.33. Vivani Medical, Inc. has a 52 week low of $0.92 and a 52 week high of $1.92.
Vivani Medical (NASDAQ:VANI - Get Free Report) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. On average, equities research analysts forecast that Vivani Medical, Inc. will post -0.41 EPS for the current year.
Institutional Investors Weigh In On Vivani Medical
A number of large investors have recently added to or reduced their stakes in VANI. Citadel Advisors LLC bought a new stake in Vivani Medical in the 3rd quarter valued at $26,000. Susquehanna International Group LLP raised its stake in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company's stock valued at $46,000 after acquiring an additional 16,200 shares during the period. Geode Capital Management LLC raised its stake in Vivani Medical by 29.6% in the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company's stock valued at $568,000 after acquiring an additional 105,398 shares during the period. Renaissance Technologies LLC raised its stake in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company's stock valued at $121,000 after acquiring an additional 53,127 shares during the period. Finally, Jane Street Group LLC bought a new stake in Vivani Medical in the 4th quarter valued at $60,000. Institutional investors own 6.78% of the company's stock.
Analysts Set New Price Targets
VANI has been the topic of a number of analyst reports. HC Wainwright dropped their price objective on Vivani Medical from $4.00 to $3.50 and set a "buy" rating on the stock in a research note on Tuesday, March 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vivani Medical in a research note on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Vivani Medical has an average rating of "Hold" and an average target price of $3.50.
View Our Latest Analysis on Vivani Medical
Vivani Medical Company Profile
(
Get Free Report)
Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.
The company's flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
